REBA MAHAFFEY: Open Payments
NPI 1215072715 · RENSSELAER, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$297 in 10 payments from 6 companies in 2025. Trend: 2023 $445 · 2024 $431 · 2025 $297
Food & beverage: $297
| Company | Payments | Amount |
|---|---|---|
| ARGENX US, INC. | 4 | $167 |
| ABBVIE INC. | 2 | $31 |
| Octapharma USA, Inc. | 1 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| SpringWorks Therapeutics, Inc. | 1 | $22 |
| Genentech USA, Inc. | 1 | $20 |
Products named: VYVGART, UBRELVY, PANZYGA, VYVGART HYTRULO, HYQVIA, GOMEKLI, Ocrevus Zunovo.
Industry payments across IN — which companies pay providers there.
